Page 1 of 1

FILING DATE August 28, 2003
CROUP
Examiner Initials
Name Class Subclass Filing Date If Appropria
Patent Number Issue Date Name Class Subclass Filing Date If Appropria
Patent Number Name Class Subclass Filing Date If Appropria
Patent Number Name Class Subclass If Appropria
Initials Number Source Studies Number Studies Number Studies Number Studies Number Studies Number Studies Studies Number Studies Studies Studies Number Studies Studies Studies Studies Studies Studies Number Studies Studies
MID 1. 20050260634 11/24/2005 Baldwin et al.
MD 2. 6,451,320 9/2002 Stephenne et al.
FOREIGN PATENT DOCUMENTS Document Publication Date Country Class Subclass Yes No
FOREIGN PATENT DOCUMENTS Document Publication Date Country Class Subclass Yes No
Document Number Publication Date Country Class Subclass Translation Yes No OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) /MD/ BURGESS et al., Science 257:1306-1310 (1990). 4. BURGESS et al., J. of Cell Bilogy 11:2129-2138 (1990). 5. FOWLKES et al., T-Cell Tolerance, Current Opinino in Immunology 5:873-879 (1993). 6. GILLES et al., Human Antibodies and Hybrodomas, 1(1):47-54 (1990). 7. HOOS et al., A Clinical Development Paradigm for Cancer Vaccines and Related Biologics, J. Immunotherapy 30(1):1-15 (Jan. 2007). 8. KYEWSKI et al., Intrathymic Presentation of Circulating Non-MHC Antigens by medullary Dendritic Cell An antigen-dependent Microenvironment for T Cell Differentiation, J. Exp. Med., 163:231-245 (1986). 9. LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988). 10. MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999) 11. OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004). 12. ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).
Document Number Publication Date Country Class Subclass Translation Yes No OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) /MD/ BURGESS et al., Science 257:1306-1310 (1990). 4. BURGESS et al., J. of Cell Bilogy 11:2129-2138 (1990). 5. FOWLKES et al., T-Cell Tolerance, Current Opinino in Immunology 5:873-879 (1993). 6. GILLES et al., Human Antibodies and Hybrodomas, 1(1):47-54 (1990). 7. HOOS et al., A Clinical Development Paradigm for Cancer Vaccines and Related Biologics, J. Immunotherapy 30(1):1-15 (Jan. 2007). 8. KYEWSKI et al., Intrathymic Presentation of Circulating Non-MHC Antigens by medullary Dendritic Cell An antigen-dependent Microenvironment for T Cell Differentiation, J. Exp. Med., 163:231-245 (1986). 9. LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988). 10. MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999) 11. OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004). 12. ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).
Document Number Publication Date Country Class Subclass Translation Yes No OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) /MD/ BURGESS et al., Science 257:1306-1310 (1990). 4. BURGESS et al., J. of Cell Bilogy 11:2129-2138 (1990). 5. FOWLKES et al., T-Cell Tolerance, Current Opinino in Immunology 5:873-879 (1993). 6. GILLES et al., Human Antibodies and Hybrodomas, 1(1):47-54 (1990). 7. HOOS et al., A Clinical Development Paradigm for Cancer Vaccines and Related Biologics, J. Immunotherapy 30(1):1-15 (Jan. 2007). 8. KYEWSKI et al., Intrathymic Presentation of Circulating Non-MHC Antigens by medullary Dendritic Cell An antigen-dependent Microenvironment for T Cell Differentiation, J. Exp. Med., 163:231-245 (1986). 9. LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988). 10. MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999) 11. OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004). 12. ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).
Number Date Country Class Subclass Yes No OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) /MD/ 3. BOWIE et al., Science 257:1306-1310 (1990). 4. BURGESS et al., J. of Cell Bilogy 11:2129-2138 (1990). 5. FOWLKES et al., T-Cell Tolerance, Current Opinino in Immunology 5:873-879 (1993). 6. GILLIES et al.m, Human Antibodies and Hybrodomas, 1(1):47-54 (1990). 7. HOOS et al., A Clinical Development Paradigm for Cancer Vaccines and Related Biologics, J. Immunotherapy 30(1):1-15 (Jan. 2007). 8. KYEWSKI et al., Intrathymic Presentation of Circulating Non-MHC Antigens by medullary Dendritic Cell An antigen-dependent Microenvironment for T Cell Differentiation, J. Exp. Med., 163:231-245 (1986). 9. LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988). 10. MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999) 11. OKA et al., Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004). 12. ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) MD 3. BOWIE et al., Science 257:1306-1310 (1990). 4. BURGESS et al., J. of Cell Bilogy 11:2129-2138 (1990). 5. FOWLKES et al., T-Cell Tolerance, Current Opinino in Immunology 5:873-879 (1993). 6. GILLIES et al.m, Human Antibodies and Hybrodomas, 1(1):47-54 (1990). 7. HOOS et al., A Clinical Development Paradigm for Cancer Vaccines and Related Biologics, J. Immunotherapy 30(1):1-15 (Jan. 2007). 8. KYEWSKI et al., Intrathymic Presentation of Circulating Non-MHC Antigens by medullary Dendritic Cell An antigen-dependent Microenvironment for T Cell Differentiation, J. Exp. Med., 163:231-245 (1986). 9. LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988). 10. MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999). 11. OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004). 12. ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).
 BOWIE et al., Science 257:1306-1310 (1990). BURGESS et al., J. of Cell Bilogy 11:2129-2138 (1990). FOWLKES et al., T-Cell Tolerance, Current Opinino in Immunology 5:873-879 (1993). GILLIES et al.m, Human Antibodies and Hybrodomas, 1(1):47-54 (1990). HOOS et al., A Clinical Development Paradigm for Cancer Vaccines and Related Biologics, J. Immunotherapy 30(1):1-15 (Jan. 2007). KYEWSKI et al., Intrathymic Presentation of Circulating Non-MHC Antigens by medullary Dendritic Cell An antigen-dependent Microenvironment for T Cell Differentiation, J. Exp. Med., 163:231-245 (1986). LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988). MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999) OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004). ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).
MD 3. BOWIE et al., Science 257:1306-1310 (1990). 4. BURGESS et al., J. of Cell Bilogy 11:2129-2138 (1990). 5. FOWLKES et al., T-Cell Tolerance, Current Opinino in Immunology 5:873-879 (1993). 6. GILLIES et al., Human Antibodies and Hybrodomas, 1(1):47-54 (1990). 7. HOOS et al., A Clinical Development Paradigm for Cancer Vaccines and Related Biologics, J. Immunotherapy 30(1):1-15 (Jan. 2007). 8. KYEWSKI et al., Intrathymic Presentation of Circulating Non-MHC Antigens by medullary Dendritic Cell An antigen-dependent Microenvironment for T Cell Differentiation, J. Exp. Med., 163:231-245 (1986). 9. LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988). 10. MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999) 11. OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004). 12. ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).
MD 3. BOWIE et al., Science 257:1306-1310 (1990). 4. BURGESS et al., J. of Cell Bilogy 11:2129-2138 (1990). 5. FOWLKES et al., T-Cell Tolerance, Current Opinino in Immunology 5:873-879 (1993). 6. GILLIES et al.m, Human Antibodies and Hybrodomas, 1(1):47-54 (1990). 7. HOOS et al., A Clinical Development Paradigm for Cancer Vaccines and Related Biologics, J. Immunotherapy 30(1):1-15 (Jan. 2007). 8. KYEWSKI et al., Intrathymic Presentation of Circulating Non-MHC Antigens by medullary Dendritic Cell An antigen-dependent Microenvironment for T Cell Differentiation, J. Exp. Med., 163:231-245 (1986). 9. LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988). 10. MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999) 11. OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004). 12. ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).
MD 3. BOWIE et al., Science 257:1306-1310 (1990). 4. BURGESS et al., J. of Cell Bilogy 11:2129-2138 (1990). 5. FOWLKES et al., T-Cell Tolerance, Current Opinino in Immunology 5:873-879 (1993). 6. GILLIES et al.m, Human Antibodies and Hybrodomas, 1(1):47-54 (1990). 7. HOOS et al., A Clinical Development Paradigm for Cancer Vaccines and Related Biologics, J. Immunotherapy 30(1):1-15 (Jan. 2007). 8. KYEWSKI et al., Intrathymic Presentation of Circulating Non-MHC Antigens by medullary Dendritic Cell An antigen-dependent Microenvironment for T Cell Differentiation, J. Exp. Med., 163:231-245 (1986). 9. LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988). 10. MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999) 11. OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004). 12. ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).
MD 3. BOWIE et al., Science 257:1306-1310 (1990). 4. BURGESS et al., J. of Cell Bilogy 11:2129-2138 (1990). 5. FOWLKES et al., T-Cell Tolerance, Current Opinino in Immunology 5:873-879 (1993). 6. GILLIES et al.m, Human Antibodies and Hybrodomas, 1(1):47-54 (1990). 7. HOOS et al., A Clinical Development Paradigm for Cancer Vaccines and Related Biologics, J. Immunotherapy 30(1):1-15 (Jan. 2007). 8. KYEWSKI et al., Intrathymic Presentation of Circulating Non-MHC Antigens by medullary Dendritic Cell An antigen-dependent Microenvironment for T Cell Differentiation, J. Exp. Med., 163:231-245 (1986). 9. LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988). 10. MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999) 11. OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004). 12. ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).
 BURGESS et al., J. of Cell Bilogy 11:2129-2138 (1990). FOWLKES et al., T-Cell Tolerance, Current Opinino in Immunology 5:873-879 (1993). GILLIES et al.m, Human Antibodies and Hybrodomas, 1(1):47-54 (1990). HOOS et al., A Clinical Development Paradigm for Cancer Vaccines and Related Biologics, J. Immunotherapy 30(1):1-15 (Jan. 2007). KYEWSKI et al., Intrathymic Presentation of Circulating Non-MHC Antigens by medullary Dendritic Cell An antigen-dependent Microenvironment for T Cell Differentiation, J. Exp. Med., 163:231-245 (1986). LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988). MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999) OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004). ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).
 FOWLKES et al., T-Cell Tolerance, Current Opinino in Immunology 5:873-879 (1993). GILLIES et al.m, Human Antibodies and Hybrodomas, 1(1):47-54 (1990). HOOS et al., A Clinical Development Paradigm for Cancer Vaccines and Related Biologics, J. Immunotherapy 30(1):1-15 (Jan. 2007). KYEWSKI et al., Intrathymic Presentation of Circulating Non-MHC Antigens by medullary Dendritic Cell An antigen-dependent Microenvironment for T Cell Differentiation, J. Exp. Med., 163:231-245 (1986). LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988). MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999) OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004). ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).
 GILLIES et al.m, Human Antibodies and Hybrodomas, 1(1):47-54 (1990). HOOS et al., A Clinical Development Paradigm for Cancer Vaccines and Related Biologics, J. Immunotherapy 30(1):1-15 (Jan. 2007). KYEWSKI et al., Intrathymic Presentation of Circulating Non-MHC Antigens by medullary Dendritic Cell An antigen-dependent Microenvironment for T Cell Differentiation, J. Exp. Med., 163:231-245 (1986). LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988). MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999) OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004). ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).
 HOOS et al., A Clinical Development Paradigm for Cancer Vaccines and Related Biologics, J. Immunotherapy 30(1):1-15 (Jan. 2007). KYEWSKI et al., Intrathymic Presentation of Circulating Non-MHC Antigens by medullary Dendritic Cell An antigen-dependent Microenvironment for T Cell Differentiation, J. Exp. Med., 163:231-245 (1986). LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988). MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999) OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004). ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).
 Immunotherapy 30(1):1-15 (Jan. 2007). 8. KYEWSKI et al., Intrathymic Presentation of Circulating Non-MHC Antigens by medullary Dendritic Cell An antigen-dependent Microenvironment for T Cell Differentiation, J. Exp. Med., 163:231-245 (1986). 9. LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988). 10. MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999) 11. OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004). 12. ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).
 KYEWSKI et al., Intrathymic Presentation of Circulating Non-MHC Antigens by medullary Dendritic Cell An antigen-dependent Microenvironment for T Cell Differentiation, J. Exp. Med., 163:231-245 (1986). LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988). MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999) OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004). ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).
An antigen-dependent Microenvironment for T Cell Differentiation, J. Exp. Med., 163:231-245 (1986). 9. LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988). 10. MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999) 11. OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004). 12. ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).
 LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988). MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999) OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004). ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).
 MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999) OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004). ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).
Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999) 11. OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004). 12. ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).
 OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004). ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).
vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004). 12. ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).
12. ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).
(Sept. 2004).
13 TAO et al. The L of Immunology 143(8):2505-2601 (1090)
17. 17. Ot al., 1 lie 3. of minimiology 145(6).2373-2001 (1707).
14. TSURUMA et al., Peptide-based vaccination for colorectal cancer, Expert Opin. Biol. Ther. 5(6):799-807
(2005).
15. Protein GenPep Accession Number: NP 005161.1
16. Protein GenPep Accession Number: AAB86993.1
ZHANG et al., Induction of Specific T Cell Tolerance by Fas Ligand-Expressing Antigen-Presenting Cells,
of Immunology 162:1423-1430 (1999).
EXAMINER /Minh Tam Davis/ (04/05/2007) DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through
citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.